KYMR
USDKymera Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$55.800
Kõrge
$61.580
Madal
$55.660
Maht
0.77M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
4.3B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.75M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90
Guggenheim analyst Brad Canino assumes Kymera Therapeutics with a Buy rating and announces Price Target of $90.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $75
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics with a Buy and raises the price target from $59 to $75.
Mizuho Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $81
Mizuho analyst Joseph Catanzaro initiates coverage on Kymera Therapeutics with a Outperform rating and announces Price Target of $81.
Seotud aktsiad
HOLO
MicroCloud Hologram Inc. Ordinary Shares
REGCO
Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock
DT
Dynatrace Inc.
DINO
HF Sinclair Corporation
TNYA
Tenaya Therapeutics Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.